Premium
Linoleic acid amides: Effect on cholesteremia and atherosclerosis
Author(s) -
Kritchevsky David,
Tepper Shirley A.,
Story Jon A.
Publication year - 1977
Publication title -
lipids
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.601
H-Index - 120
eISSN - 1558-9307
pISSN - 0024-4201
DOI - 10.1007/bf02532966
Subject(s) - endogeny , triglyceride , chemistry , cholesterol , clinical chemistry , lipidology , medicine , linoleic acid , endocrinology , basal (medicine) , excretion , biochemistry , fatty acid , biology , insulin
Several of a series of linoleic acid amides have been reported to inhibit cholesterol‐induced atherosclerosis in rabbits. The three amides which have been studied to the greatest extent are (in order of increasing activity) N‐cyclohexyl linoleamide (AC23), N(α methylbenzyl) linoleamide (AC223), and N[α‐phenyl‐β‐(p‐tolyl) ethyl] linoleamide (AC485). We have found AC223 to inhibit cholesterol absorption in rats and to slightly inhibit exogenous but not endogenous cholesteremia in rabbits. In a fiber‐free diet, AC223 reduces serum cholesterol and liver triglyceride levels. Rats were also fed a basal semipurified diet with and without AC223. Fecal excretion of labeled exogenous (as [ 14 C] cholesterol) or endogenous (as [ 14 C] mevalonolactone) steroid was 44 and 43% higher in drug treated groups. The mechanism of hypocholesteremic action of the linoleamides appears to involve inhibition of cholesterol absorption.